755.65 4.60 (0.61%)
NSE Nov 30, 2021 14:19 PM
Volume: 2.8M
 

755.65
0.61%

Highlights:

  • Consolidated sales from operations at Rs. 95,567 million, growth of 13% over Q2 last year
  • India sales at Rs. 31,878 million, up 26% over same quarter last year
  • US finished dosage sales at US$ 361 million, growth of 8% over Q2 last year
  • Emerging Markets sales at US$ 243 million, up by 16% over Q2 last year
  • Rest of World sales at US$ 188 million, up by 5% over same quarter last year
  • R&D investments at Rs. 5,364 million compared to Rs. 6,127 million for Q2FY21
  • EBITDA at Rs. 25,608 million, up by 21% over Q2 last year, with resulting EBITDA margin of 26.8%
  • Net profit for the quarter was at Rs. 20,470 million, up 29% compared to adjusted net profit of Q2 last year and up 13% versus reported net profit YoY 
  • Consolidated sales from operations at Rs. 192,262 million, growth of 20% over same period last year.
  • India sales at Rs. 64,961 million, up by 32% over H1 last year.
  • US finished dosage sales at US$ 741 million up by 20% over H1 last year.
  • Emerging Markets sales at US$ 461 million up by 20% over H1 last year.
  • Rest of World sales at US$ 373 million, up by 18% over H1 last year.
  • EBITDA at Rs. 53,325 million up 38% over H1 last year, with resulting EBITDA margin of 27.7%.
  • Excluding the exceptional items, adjusted net profit for H1FY22 was at Rs. 40,263 million, up 47% YoY.
  • Reported net profit for H1FY22 was at Rs. 34,912 million compared to Rs. 1,572 million for H1 last year.

    Dilip Shanghvi, Managing Director of the Company said, “Following our good Q1 performance, we have sustained the positive momentum in Q2 with a topline growth of 13% YoY, driven by a broad-based growth across multiple geographies. Our global specialty business has grown by 43% over Q2 last year. Ilumya has grown both YoY and sequentially. Our India business continues to do well with a growth of 26% YoY. We remain steadfast in our focus on growing our overall business and simultaneously strengthening our global specialty portfolio. The recent launch of Winlevi in US and Ilumya in Canada is a step forward in this direction.”

Result PDF

default
Number of FII/FPI investors increased from 759 to 827 in Sep 2021 qtr.
Recommended
More from Sun Pharmaceutical Industries Ltd.